Ovarian Cancer Coverage from Every Angle

ASCO20: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

By: Melissa Steele-Ogus
Posted: Monday, June 22, 2020

According to a randomized, phase III trial, presented during the ASCO20 Virtual Scientific Program (Abstract 6001), secondary cytoreductive surgery in selected patients with recurrent ovarian cancer may improve progression-free survival. Rongyu Zang MD, PhD, of Fudan University, Shanghai, and collaborators from other Chinese hospitalsreported that this surgery may ultimately offer a long-term survival benefit, based on their interim analysis of accumulated treatment-free survival.

A total of 357 patients with a primary relapse of ovarian cancer who had at least a 6-month platinum-free interval were randomly assigned for the study. Patients underwent either secondary cytoreductive surgery followed by chemotherapy or chemotherapy alone. Primary study endpoints were progression-free and overall survival. A secondary endpoint was accumulated treatment-free survival, defined as the time of surgery and chemotherapy subtracted from the overall survival time.

The 60-day mortality rate in both groups was 0%. The median progression-free survival was 17.4 months with secondary cytoreductive surgery and chemotherapy versus 11.9 months with chemotherapy alone (hazard ratio = 0.58; 95% confidence interval = 0.45–0.74; P < .001). The median accumulated treatment-free survival was unreached with surgery; 39.5 months was observed with chemotherapy alone (hazard ratio = 0.59; 95% confidence interval = 0.38–0.91). Patients who had surgery were found to have a better accumulated treatment-free survival than those who did not, with a restricted mean survival time of 60 to 72 months and 6.2 months to 4.2 months, respectively. Both overall survival and accumulated treatment-free survival data were not yet mature.

Disclosure: The authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.